BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34180463)

  • 1. Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis.
    Kim JY; Hwang D; Jang M; Rhee CS; Han DH
    Rhinology; 2021 Aug; 59(4):352-359. PubMed ID: 34180463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study.
    Tu Y; Zhang H; Zhao L; Jin P; Zi X; Li T; Shi L; Zhi L
    J Laryngol Otol; 2019 Mar; 133(3):213-219. PubMed ID: 30674357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
    Yang L; Yang Y; Xu Q; Zhang W; Jiang Q; Li W; Wang Y; Ma D; Lin X; Sun B; Zhu R
    Front Immunol; 2021; 12():786738. PubMed ID: 35197963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis.
    Phinyo P; Krikeerati T; Wongyikul P; Lao-Araya M; Thongngarm T
    Asian Pac J Allergy Immunol; 2022 Dec; 40(4):337-352. PubMed ID: 36278778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
    Meteran H; Backer V
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
    [No Abstract]   [Full Text] [Related]  

  • 12. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period.
    Soh JY; Thalayasingam M; Ong S; Loo EX; Shek LP; Chao SS
    J Laryngol Otol; 2016 Mar; 130(3):272-7. PubMed ID: 26781592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. House dust mite sublingual immunotherapy in allergic rhinitis.
    Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
    Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 300 IR house dust mite immunotherapy as a function of disease activity: Tertile analysis in clinical trials.
    Devillier P; Demoly P; Gentil C; Bergmann KC; Casale TB; Okamoto Y; Pfaar O
    Clin Exp Allergy; 2024 May; 54(5):329-338. PubMed ID: 38545699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma.
    Jutel M; Brüggenjürgen B; Richter H; Vogelberg C
    Allergy; 2020 Aug; 75(8):2050-2058. PubMed ID: 32080856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
    Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
    Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. House dust mite subcutaneous immunotherapy has sustained long-term effectiveness on allergic rhinitis and asthma: A 10-year follow-up.
    Rodriguez-Plata E; Callero Viera A; Ruiz-Garcia M; Gomez-Cardenosa A; Nieto E; García-Robaina JC
    Immun Inflamm Dis; 2023 Oct; 11(10):e1004. PubMed ID: 37904678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
    Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.